Adjuvant effect of IRES-based single-stranded RNA on melanoma immunotherapy

Hye Won Kwak1,2,3, So-Hee Hong4, Hyo-Jung Park1,2, Hyeong-Jun Park1,2,3, Yoo-Jin Bang1,2,3, Jae-Yong Kim1,2,3, Yu-Sun Lee1,2, Seo-Hyeon Bae1,2, Hyunho Yoon1,2* and Jae-Hwan Nam1,2,3*

Abstract
Background: Adjuvant therapies such as radiation therapy, chemotherapy, and immunotherapy are usually given after cancer surgery to improve the survival of cancer patients. However, despite advances in several adjuvant therapies, they are still limited in the prevention of recurrences.

Methods: We evaluated the immunological effects of RNA-based adjuvants in a murine melanoma model. Single-stranded RNA (ssRNA) were constructed based on the cricket paralysis virus (CrPV) internal ribosome entry site (IRES). Populations of immune cells in bone marrow cells and lymph node cells following immunization with CrPV-IRES-ssRNA were determined using flow cytometry. Activated cytokine levels were measured using ELISA and ELISpot. The tumor protection efficacy of CrPV-IRES-ssRNA was analyzed based on any reduction in tumor size or weight, and overall survival.

Results: CrPV-IRES-ssRNA treatment stimulated antigen-presenting cells in the drain lymph nodes associated with activated antigen-specific dendritic cells. Next, we evaluated the expression of CD40, CD86, and XCR1, showing that immunization with CrPV-IRES-ssRNA enhanced antigen presentation by CD8α+ conventional dendritic cell 1 (cDC1), as well as activated antigen-specific CD8 T cells. In addition, CrPV-IRES-ssRNA treatment markedly increased the frequency of antigen-specific CD8 T cells and interferon-gamma (IFN-γ) producing cells, which promoted immune responses and reduced tumor burden in melanoma-bearing mice.

Conclusions: This study provides evidence that the CrPV-IRES-ssRNA adjuvant has potential for use in therapeutic cancer vaccines. Moreover, CrPV-IRES-ssRNA possesses protective effects on various cancer cell models.

Keywords: Murine melanoma model, Adjuvant immunotherapy, CrPV-IRES-ssRNA, RNA vaccine, Antigen-presenting cells

Introduction
The ideal vaccine protects against infection by inducing a long-term immunological memory response to the target antigen [1]. However, some vaccines can fail to elicit a sufficient immune response and, therefore, cannot protect against infection or disease recurrence. Various immune stimulants, namely adjuvants, have been developed that increase both innate and humoral responses [2]. Immune stimulation can generally be achieved through three signaling mechanisms [3, 4]: 1) Increased antigen presentation and antigen uptake [5–7] by allowing the interaction of pattern of recognition receptors (PRRs) such as Toll-like receptors (TLRs), retinoic
acid-inducible gene I (RIG-I)-like receptors (RIG-Is) & NOD-like receptors, with pattern associated molecular pathogeneses [8–11]; 2) Activation of the co-stimulatory molecules of antigen-presenting cells (APCs), such as CD40, CD80, and CD86 cells [11, 12]; 3) Stimulation of naïve T cells to differentiate into Th1/Th2 cells and the modulation of antigen-specific antibody responses via cytokine activation and PRR stimulation [13–16].

Aluminum (alum)-containing supplements act as exogenous damage-associated molecular patterns (DAMPs), triggering an immune response and causing tissue damage [17]. Aluminum exposure has been shown to induce antibody-mediated responses and the proliferation of CD4 T cells [18]. Alum combined with antigenic proteins enhanced the differentiation of Th2 cells and increased antigen-specific follicular T cells [14]. On the other hand, nucleic acid-based adjuvants generally induce an immune response through the recognition of foreign agents and non-self-nucleic acids through TLRs located on the surface of APCs (TLR1, 2, 4, 5, and 6) and endosomal membranes (TLR3, 7, 8, and 9) [19]. RNA-based adjuvants have been reported to recognize a variety of TLRs, such as TLR3 for dsRNA and TLR7/8 for ssRNA [20, 21]. Poly(I:C) consists of double-stranded RNA, which generally induces antiviral effects by stimulating TLR3 signaling [22]. It also enhances type I interferon and Th1-related cytokines [13, 23], and subsequently activates co-stimulatory molecules on conventional dendritic cells (cDCs), which affects CD8 T cell activation [24–26]. However, poly(I:C) has significant drawbacks, including severe side effects, an undefined structure, and a lack of homogeneity [27]. In contrast to poly(I:C), synthetic or natural ssRNA is recognized by TLR7/8 in plasmacytoid dendritic cells (pDCs) which in turn produce type I interferon and proinflammatory cytokines [24, 25]. Activated TLR7/8 may also promote the activation of CD8 and effector T cells [26, 28].

Recently, an ssRNA-based adjuvant, RNA adjuvant® has been developed. It consists of an ssRNA, a non-coding site, and non-capped RNA sequence containing with poly (U) repeats, with added cationic peptides for stabilization. RNA adjuvant® therapy has been shown to enhance antigen-specific antibody responses and balanced Th1/Th2 cell responses [29]. It also induced immune responses via TLRs, RIG signaling, and MyD88-/MAVS-dependent mechanisms [29, 30]. The induction of these signaling pathways contributes to the activation of human CD141+ DCS, pDCs, monocytes, and CD8 T cells [31–33]. RNA adjuvant® has been incorporated into various types of vaccine delivery systems, including peptide, subunit, and virus-like particle vaccines to induce immune responses similar to poly(I:C) adjuvant [29, 34]. Our group has previously reported that ssRNA-based adjuvant treatment effectively increased the efficacy of various prophylactic vaccines, including inactivated, sub-unit, virus-like particle, and even live-attenuated vaccines by inducing balanced Th1/Th2 cell responses [35–37].

An adjuvant can be used to enhance the immune response of a therapeutic vaccine. The RNA-based adjuvant increased the antibody response, which is an indicator of efficacy for the preventive vaccine, and also increased the antigen-specific T cell anti-tumor immune response [34]. In this study, the cricket paralysis virus internal ribosome entry site (CrPViring)-ssRNA was established and administered to mice challenged with murine melanoma cells. The National Center for Health Statistics reported that approximately 90,000 cases of melanoma occur annually in the USA [38]. Melanoma is the most common type of skin cancer, which occurs in melanocytes that produce the melanin responsible for variations in skin color [39]. Melanin is most abundant in the epidermis but is also found in the irises, inside the nose or throat, and throughout the internal organs [40]. Although the etiology of all types of melanomas is not currently elucidated, it is known that sun-induced ultraviolet (UV) radiation promotes the growth of melanoma [41]. Most early-stage melanomas can be treated successfully with surgery; however, this is often combined with chemotherapy or targeted therapy for metastatic melanoma [39]. Unfortunately, the survival rate of patients is still low due to recurrence after treatment, and thus, there is an urgent need for better strategies to treat melanoma. Here, we evaluate the effects of CrPViring-ssRNA as an adjuvant therapy that can induce antigen-specific T cell responses. In addition, we identify the immunological mechanisms of CrPViring-ssRNA activity and investigate the efficacy of CrPViring-ssRNA as an adjuvant in melanoma treatment.

**Material and methods**

**Mice and immunization**

Six-week-old female C57BL/6 mice were purchased from Dae-Han Bio-Link (Eumseong, Korea). Mice were maintained under specific pathogen-free conditions with a 12 h light/dark cycle. According to the National Institutes of Health (NIH) guidelines, euthanasia of rodents was performed using carbon dioxide at a fill rate of 30–70% of the chamber volume per minute. All animal studies were conducted according to the guidelines of the Institutional Animal Care at the Catholic University of Korea (CUK-IA-CUC-2021–025-01).

To evaluate adjuvant therapy APC response in relation to total lymph node cells, mice were immunized intramuscularly with either Alum antigen in a 1:1 ratio (Thermo Fisher Scientific, Waltham, MA, USA), 20 µg poly(I:C) (Sigma Aldrich, St. Louis, MO, USA), or 20 µg
In the APCs activation test, mice were immunized intramuscularly with either saline, 20 µg poly(I:C), 20 µg ssRNA, or 100 µg ssRNA (Fig. 1). To test antigen-specific responses to Ova protein, mice were immunized intramuscularly twice with an interval of two weeks (day 0 and on day 14) with 50 µg Ova protein in combination with either 20 µg poly(I:C) or 20 µg ssRNA. Saline injection was used as a control (Fig. 2). In the T-cell activation test, mice were immunized intramuscularly twice with an interval of two weeks (day 0 and on day 14) with either 50 µg Ova protein in isolation, 50 µg Ova protein with Alum antigen in a 1:1 ratio or 50 µg Ova protein with 20 µg ssRNA (Fig. 3).

In vitro transcription and RNA purification
The DNA platform was constructed based on the IRES intergenic region and the SV40 late-polyadenylation signal sequences. DNA templates were linearized using Not I (Enzynomics, Daejeon, Korea). For ssRNA production, in vitro transcription was assessed using the EZ T7 High Yield In Vitro Transcription Kit (Enzynomics), according to the manufacturer’s instructions.

Flow cytometry and antibodies
To confirm the presence of the OVA tetramer, splenocytes and the inguinal lymph node lymphocytes of the mice were harvested and blocked using CD16/CD32 (eBioscience, Waltham, MA, USA; Thermo Fisher Scientific Inc.) for 20 min at 4 °C, and then stained with the following antibodies for 20 min at 4 °C: H-2 Kb Ova tetramer with the Ova 257–264 epitope SIINFEKL. This was provided by the National Institutes of Health (NIH), and we followed the manufacturers’ protocol.

For surface staining, splenocytes and isolated immune cells from muscle and the inguinal lymph node were stained with the following antibodies for 15 min: CD8a (clone KT15, MBL), Fixable Viability Dye eFluor520 (eBioscience), CD8 (Clone 53–6.7, Invitrogen Waltham, MA, USA), CD44 (Clone IM7, Invitrogen), and CD62L (Clone MEL 14, BD Biosciences, Waltham, MA, USA). Prior to staining for the transcription factor Ki-67 (clone SolA15; eBioscience), the cells were permeabilized using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) for 30 min at 4 °C.
CrPVIRES-ssRNA activates dendritic cells in draining inguinal lymph nodes. A Mouse bone marrow-derived dendritic cells (BMDCs) were stimulated with CrPVIRES-ssRNA or poly(I:C) for 24 h. Cell activation was measured by flow cytometry using antibodies specific to CD40, CD80, and CD86. B Mice were intramuscularly immunized once with poly(I:C) (20 µg) and CrPVIRES-ssRNA (20 µg and 100 µg) for 24 h (n = 5). C Percentages of co-stimulatory molecules (CD40, CD80, and CD86) of CD11c⁺ DCs in lymphocytes isolated from draining inguinal lymph nodes. D, E Percentages of activation markers of DCs (cDC1, cDC2, pDC) in CD40⁺ cells (D) and CD80⁺ cells (E). Dendritic subsets were analyzed by flow cytometry using CD8a⁺, CD8⁻, and B220⁺. Data were represented as mean ± SD. Statistical significance was indicated by *p < 0.05, **p < 0.01, and ***p < 0.005.
To determine the activation of macrophages, dendritic cells, and B and T cells, the isolated splenocytes and lymphocytes were blocked using CD16/CD32 (eBioscience; Thermo Fisher Scientific Inc.) for 20 min at 4 °C, and were stained using Fixable Viability Dye eFluor520 (eBioscience), F4/80 (clone BM8, eBioscience), CD11c (clone N418, eBioscience), CD11b (clone M1/70, eBioscience), Ova-FITC (Thermo Fisher Scientific), CD40 (clone 1C10, eBioscience), CD80 (clone 16-10A1, Biolegend, San Diego, CA, USA), CD86 (clone GL1, Biolegend), XCR1 (clone ZET, Biolegend), CD8a (clone 53–6.7, eBioscience), CD19 (clone 6D5, Biolegend), B220 (clone RA3-6B2, BD Biosciences), CD4 (clone GK1.5, Invitrogen), and CD8a (clone 53–6.7, Invitrogen) for 20 min at 4 °C without exposure to light. Stained cells were fixed with 1%
paraformaldehyde. Cells were analyzed using the FACS Aurora (Cytek Biosciences, Fremont, CA, USA), CytoFLEX Flow Cytometer (Beckman Coulter, CA, USA), and the data were analyzed using Spectroflo (Cytek Biosciences), FlowJo (Tree Star, Inc., Ashland, OR, USA), and CytExpert (Beckman Coulter).

**Splenocyte cell culture and Enzyme-Linked ImmunoSpot (ELISpot)**

Splenocytes were stimulated with 4 µg/well Ova 323–339 CD4-specific T cell (ISQAVHAHAEEINEAGR) and Ova 257–264 CD8-specific T cell epitope peptide (SIINFEKL) for 48 h at 37 °C. The OVA peptides were synthesized using Peptron (Daejeon, Korea). The ELISPOT assays for the detection of IFN-γ-secreting T cells were performed using mouse IFN-γ (Mabtech, Stockholm, Sweden), according to the manufacturer’s instructions.

**Preparation of bone marrow-derived dendritic cells (BMDCs)**

The cells were prepared as previously described [42]. Bone marrow nucleated cells (1 × 10⁶ cells/ml) were seeded in a modified 5 ml RPMI 1640 (Gibco; Thermo Fisher Scientific Inc.), Waltham, MA, USA) medium containing 10% FBS (Gibco), in 6-well plates. Subsequently, 100 ng/ml mouse
recombinant GM-CSF (Granulocyte–Macrophage Colony-Stimulating Factor) (Peprotech, New Jersey, United States) and 50 ng/ml mouse recombinant IL-4 (Peprotech) were added to the medium to stimulate BMDCs.

Mouse cancer challenge
B16-Ova cells (5 × 10^5 cells) were subcutaneously injected into 6-week-old female C57BL/6 mice on day 0. On day 7 after tumor inoculation, tumor size was measured and the mice were intramuscularly immunized with one of the following: Ova protein (50 µg) in isolation, Ova protein (50 µg) in combination with poly(I:C) (20 µg), or Ova protein (50 µg) in combination with ssRNA (20 µg), at an interval of 2 days (days 9, 11, 13, and 15) to total 5 immunization treatments (n = 5). The mice were sacrificed when the size of tumor exceeded 1 cm^3 according to animal ethical standards. On day 31 after the tumor challenge, the weight of the tumors from the sacrificed mice was measured.

Statistical analyses
All data are expressed as the mean ± SD. One-way ANOVA was used to assess the significance of differences among treatment groups; if significant deviations from variance homogeneity were detected using the Levene test, then the nonparametric Kruskal–Wallis H test was performed. The student’s t-test was used to assess significant differences between the two groups; if significant deviations from variance homogeneity were detected using the Levene test, then the nonparametric Mann–Whitney U test was performed. Statistical analyses were conducted using SPSS for Windows (release 14.0 K, IBM, Armonk, NY). Differences were considered significant at values of *p < 0.05, **p < 0.01, and ***p < 0.005.

Results
CrPV<sub>IRES</sub>-ssRNA recruits immune cells from the inguinal lymph node
The immune response induced by CrPV<sub>IRES</sub>-ssRNA was assessed using poly(I:C) and alum as positive controls. The immune cells in the drain inguinal lymph nodes were counted at an earlier time point (Fig. 1A, B). The CrPV<sub>IRES</sub>-ssRNA treated group demonstrated an increase in the number of cells isolated from drain inguinal lymph nodes 24 h after immunization (Fig. 1A, B; Supplementary Fig. S1A). The Poly(I:C) treatment group showed a similar increase in cells isolated from the drain inguinal lymph nodes, while no increase in immune cells was observed in the alum treated group (Fig. 1B). However, the proportion of CD4<sup>+</sup>/CD8<sup>+</sup> T cells in drain lymph nodes did not change significantly in any of the groups (Supplementary Fig. S1B, C). Subsequently, the antigen uptake ability of activated APCs was evaluated using the fluorescein isothiocyanate-conjugated Ova (Ova-FITC). The antigen uptake ability was significantly higher in the CrPV<sub>IRES</sub>-ssRNA and poly(I:C) treated group than in the alum treated group (Fig. 1C, D). This indicates that CrPV<sub>IRES</sub>-ssRNA can act as an adjuvant by effectively recruiting antigen-presenting cells and enhancing antigen uptake.

CrPV<sub>IRES</sub>-ssRNA activates dendritic cells in drain inguinal lymph nodes
To identify the types of APCs recruited by CrPV<sub>IRES</sub>-ssRNA treatment, activation markers of dendritic cells and macrophages, such as CD40<sup>+</sup>, CD80<sup>+</sup>, and CD86<sup>+</sup>, were measured by flow cytometry. Bone marrow-derived dendritic cells (BMDCs) were treated with CrPV<sub>IRES</sub>-ssRNA and poly(I:C). The CrPV<sub>IRES</sub>-ssRNA treatment increased levels of the activation markers in a dose-dependent manner (Fig. 2A; Supplementary Fig. S2A). After we injected poly(I:C) and CrPV<sub>IRES</sub>-ssRNA intramuscularly without the antigen, inguinal lymph nodes were collected on day 1 (Fig. 2B). In the CrPV<sub>IRES</sub>-ssRNA-treated group, the expression of the co-stimulatory molecules, CD40<sup>+</sup>, CD80<sup>+</sup>, and CD86<sup>+</sup>, increased in CD11c-positive cells related to dendritic cells regardless of the concentration (Fig. 2C). However, the expression of macrophage activation markers in poly(I:C)- and CrPV<sub>IRES</sub>-ssRNA-treated groups was not significantly different from that in the control group (Supplementary Fig. S2B). Next, we investigated the dendritic cell types of drain lymph nodes affected by uptake of CrPV<sub>IRES</sub>-ssRNA treatment. The activated conventional DC1/2 (cDC1 and cDC2) and pDC in drain inguinal lymph nodes were identified using flow cytometry. The CrPV<sub>IRES</sub>-ssRNA treatment enhanced the activity of the CD8α<sup>+</sup> cDC1 activation maker, while differences in the CD8α<sup>-</sup> cDC2 and pDC markers were insignificant (Fig. 2D, E). The poly(I:C)-treated group also showed a similar pattern (Fig. 2D-E). These results revealed that CrPV<sub>IRES</sub>-ssRNA primarily increases the activity of CD8α<sup>+</sup> cDC1 cells among antigen-presenting cells.

Ovalbumin (Ova) protein formulated with CrPV<sub>IRES</sub>-ssRNA activates CD8α<sup>+</sup> cDC1
In immunology, Ova is widely used in vaccines as it is a key protein that stimulates immune responses, including allergic reactions [43]. To investigate the detailed mechanism of cDC1 activation by CrPV<sub>IRES</sub>-ssRNA treatment, we formulated a combination of CrPV<sub>IRES</sub>-ssRNA or poly(I:C) with Ova protein. After the second immunization (day 0 and day 14) with these constructs in mice, splenocytes and inguinal lymph nodes lymphocytes were harvested after one day (day 14 + 1) (Fig. 3A). Treatment of CrPV<sub>IRES</sub>-ssRNA with Ova protein resulted in enhanced expression of the co-stimulatory molecules,
CD40⁺, CD80⁺, and CD86⁺, on CD8α⁺ DC1 cell population in spleen and inguinal lymph nodes (Fig. 3B, C). Additionally, an increased expression of the chemokine receptor, XCR1⁺, which is also an activation marker of CD8α⁺ DC1 cells, was observed in the spleen and inguinal lymph node cells (Fig. 3D). This suggested that CrPVRES-ssRNA with Ova protein could act as an adjuvant therapy by activating CD8α⁺ cDC1 cells.

**CrPVRES-ssRNA formulated with Ova protein elicits production and activation of T cells**

To evaluate CrPVRES-ssRNA-mediated T-cell activation, splenocytes, and inguinal lymph nodes lymphocytes were isolated on day 7 after the second immunization (day 14 + 7) of mice with saline (Group 1; G1), Ova protein (Group 2; G2), Ova with alum (Group 3; G3), and CrPVRES-ssRNA formulated with Ova (Group 4; G4) (Fig. 4A). The population of Ova-specific CD8⁺ T cells in the spleen significantly increased in the CrPVRES-ssRNA-Ova-treated group (G4) (Fig. 4B, C). Furthermore, G4 showed statistically significant difference increased population of Ova-specific CD8 effector T cells and Ki-67⁺, a proliferation marker, compared to G2 in the drain inguinal lymph nodes (Fig. 4D). IFN-γ is an inflammatory cytokine with anti-tumor function that is related to innate and adaptive immune responses [44]. In the CrPVRES-ssRNA-Ova-treated group, the frequency of IFN-γ-secreting cells after stimulation with CD4 and CD8 specific peptides was significantly higher than that of G2 and G3 (Fig. 4E). These data suggest that CrPVRES-ssRNA treatment enhances dendritic cell uptake and activates CD8α⁺ cDC1, especially when administered alone or in combination with antigen, leading to activated antigen-specific CD8 T cells.

**CrPVRES-ssRNA reduces tumor burden in a murine melanoma model**

To test the in-vivo efficacy of CrPVRES-ssRNA, mice were challenged with B16-Ova cells. Tumor-bearing
mice (ten in each group) were inoculated intramuscularly with Ova protein, Ova protein-poly(I:C), and Ova protein-CrPV<sup>RES</sup>-ssRNA. In the poly(I:C)- and CrPV<sup>RES</sup>-ssRNA-treated groups, there was a decrease in cancer growth and weight compared to the control (Ova protein-treated) group (Fig. 5A-C). Mouse weight was not significantly different between groups (Fig. 5D). In addition, CrPV<sup>RES</sup>-ssRNA and poly(I:C) treatment increased the survival rate. (Supplementary Fig. S3A).

These results suggest that immune cells augmented by CrPV<sup>RES</sup>-ssRNA may exhibit potential anti-tumor effects by protecting against melanoma growth (Fig. 6).

**Discussion**

Cancer immunotherapy has been actively studied as a promising strategy in cancer treatment. However, there are many limitations in treating cancer such as immune tolerance and insufficient immune response. Adjuvant
therapies that increase the immune response may play an important role in overcoming these limitations. For instance, cancer vaccines that introduce tumor antigens to APCs can enhance anti-tumor immune responses by attenuating immune resistance and generating sufficient immune responses in the cancer environment [45]. Dendritic cells, a type of APC activated by cancer vaccines, can initiate immune cell migration and activation [46], leading to the activation of antigen-specific CD4/CD8 T cells that can directly attack cancer.

Previous studies have reported that double-stranded RNA may be an important substance in cancer vaccines and may itself increase immune responses via TLR3 and RIG-1s [47]. Previous findings have confirmed that the CrPV-IRES-ssRNA increased the expression of CXCR1, an inflammatory dendritic cell marker, around the injection site [35, 48]. In this study, we investigated the mechanism of the novel viral IRES-derived CrPV-IRES-ssRNA in inducing immune responses [35]. CrPV-IRES-ssRNA gradually increased the total cell population such as DCs, macrophages, and B cells in the draining lymph nodes. Moreover, it enhanced the activation of APCs (Fig. 1). In general, activated APCs have been reported to enhance antigen presentation to major histocompatibility (MHC) molecules, leading to adaptive and innate immunity [12, 49, 50]. Expression analysis of co-inflammatory signature proteins revealed that CrPV-IRES-ssRNA increased antigen uptake by dendritic cells. Notably, CrPV-IRES-ssRNA treatment significantly increased the co-stimulatory molecules of CD8+ cDC1, such as CD40+, CD80+, CD86+, and XCR1+ (Figs. 2 and 3), suggesting that CrPV-IRES-ssRNA is strongly associated with specific types of DCs. It is known that CD8+ cDC1 cells contribute to the effective cross-presentation of antigens [51–53] and the induction of Th1 responses [54, 55], as well as enhancing the production of chemokines associated with effector and memory CTLs [56, 57]. Functionally, expression of XCR1+ on CD8+ cDC1 leads to an increase in the proliferation and activation of antigen-specific CD8+ T cells and secretion of IFN-γ [58, 59]. These results indicated that CrPV-IRES-ssRNA can induce a general immune response by stimulating APCs, especially cDC1 cells, to induce activation of effector T cells.

In addition, this study investigated whether CrPV-IRES-ssRNA induces antigen-specific T-cell responses. CrPV-IRES-ssRNA significantly increased the total population and proliferative capacity of antigen-specific effectors. CD8 T cells in the draining lymph nodes (Fig. 4D), suggesting that CrPV-IRES-ssRNA activates antigen-specific CD8 T cells by stimulating the maturation of cDC1 cells. It has been reported that cDC1 cells induce the expansion of CD8 T cells primarily by presenting specific antigens expressed on MHC class I molecules [60]. The activation of CD8 T cells was involved in anti-tumor immune responses [61, 62] and anti-viral responses [63]. Interestingly, CrPV-IRES-ssRNA increased the frequency of IFN-γ-secreting cells (Fig. 4E). In addition, although not statistically significant in the spleen of challenged mice, a slight increase the population of IFN-γ-secreting cells can be seen than in the negative control group (G1) (Supplementary Fig. S3B). It has been observed that antigen-specific CD4 and CD8 T cells inhibited the growth of melanoma cells, mainly by inducing IFN-γ cytokines that increase tumor-infiltrating lymphocytes and activating APCs to kill melanoma cells [64]. Indeed, CrPV-IRES-ssRNA delayed the growth of cancer cells in a murine melanoma model (Fig. 5).

**Conclusions**

In conclusion, a novel cricket paralysis virus IRES-based single-stranded RNA may play an essential role as an adjuvant in inducing cDC1-CD8 T cell-mediated immune responses in cancer immunotherapy. Based on the immunological mechanism induced by the ssRNA adjuvant (Fig. 6), it can be applied to various cancer vaccines and adjuvant cancer treatment regimes.

**Abbreviations**

- ssRNA: Single-stranded RNA
- CrPV: Cricket paralysis virus
- IRES: Internal ribosome entry site
- cDC1: Conventional dendritic cell 1
- pDCs: Plasmacytoid dendritic cells
- UV: Ultraviolet
- Ova-FITC: Fluorescein isothiocyanate-conjugated Ova
- cDC1, cDC2: Conventional DC1/2
- PRRs: Pattern recognition receptors
- TLRs: Toll-like receptors
- RIG-I: Retinoic acid-inducible gene I
- RIG-Is: RIGI-like receptors
- APCs: Antigen-presenting cells
- cDCs: Conventional dendritic cells
- ssRNA: Single-stranded RNA
- CrPV: Cricket paralysis virus
- IRES: Internal ribosome entry site
- cDC1: Conventional dendritic cell 1
- PRRs: Pattern recognition receptors
- TLRs: Toll-like receptors
- RIG-I: Retinoic acid-inducible gene I
- RIG-Is: RIGI-like receptors
- APCs: Antigen-presenting cells
- cDCs: Conventional dendritic cells
- pDCs: Plasmacytoid dendritic cells
- UV: Ultraviolet
- Ova-FITC: Fluorescein isothiocyanate-conjugated Ova
- cDC1, cDC2: Conventional DC1/2

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-10140-2.
Acknowledgements
Not applicable

Authors’ contributions
H.W. K. and J.-H. N. conceived and supervised the research and designed the experiments. H.W.K and Y.-B. confirmed the efficacy of adjuvant in ex vivo. H.W.K., J.-Y. K., Y.-S. L., and S.-H. B. performed the vaccinations and sacrificed in mice. H.W.K. and H.-J. P. flow cytometry analysis and interpreted the data. S.-H. H., H.-J. P., H. Y., and J.-H.N. assisted in the adjustments of directions and interpretation of the mechanistic aspects of the results. H.W.K., H. Y., and J.-H.N. contributed to writing the manuscript. All authors read and approved the final manuscript.

Funding
J.-H.N. was supported by the Research Unit of Korea Center for Disease Control and Prevention grant (grant number 2020-ERS303-02), the National Research Foundation of Korea (NRF) grant (grant number NRF-2021M3E5E308588), the Ministry of Food and Drug Safety grant (grant number 22213MFDS421) and partially supported by the Brain Korea 21 Plus Program, H.-J.P is supported by the grant from the Ministry of Food and Drug Safety in 2022 (grant number 22203MFDS404).

Availability of data and materials
All data generated and analyzed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate
All animal studies were conducted according to the guidelines of and with the ethical approval of the Institutional Animal Care at the Catholic University of Korea (CUK-IACUC-2021-023-01). All methods were carried out in accordance with ARRIVE guidelines and regulations (https://arriveguidelines.org). All methods were reported in accordance with ARRIVE guidelines for the reporting of animal experiments.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Medical and Biological Sciences, The Catholic University of Korea, 43-1 Yeolgeok-dong, Wonmi-gu, Bucheon 14662, Republic of Korea. 2BK Plus Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea. 3SML biopharm, Gyeonggi-do, Gwangmyeong, Republic of Korea. 4Department of Microbiology, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.

Received: 19 July 2022 Accepted: 27 September 2022 Published online: 05 October 2022

References
1. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–96.
2. Guerrero Manriquez GG, Tuero I. Adjuvants: friends in vaccine formulation against infectious diseases. Hum Vaccin Immunother. 2021;17(10):3539–50.
3. Pasqualet AD, Preiss S, Silva FTDo, Garçon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines. 2015;3(2):320–43.
4. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509–17.
5. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol. 2012;12(7):479–91.
6. Schijns VEJG. Immunological concepts of vaccine adjuvant activity: Commentary. Curr Opin Immunol. 2000;12(4):456–63.
7. Kubelkova K, Macela A. In innate Immune Recognition: An Issue More Complex Than Expected. Front Cell Infect Microbiol. 2019:9:241.
8. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science. 2006;314(5807):1936–8.
9. Apostolić JDS, Lundellari VAS, Coirada FC, Boscardin SB, Rosa DS: Adjuvants: Classification, Modus Operandi, and Licensing. J Immunol Res. 2016;2016:1459394.
10. Franchi L, Park JH, Shaw MH, Marina-Garcia N, Chen G, Kim YG, Núñez G. Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol. 2008;10(1):1–8.
11. Reed SG, Berothet S, Coler RN, Friedie M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009;30(1):23–32.
12. Ho NL, Huis in’t Veld LGM, Raajmakers TK, Adema GJ. Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines? Front Immunol. 2018;2874.
13. Longhi MP, Thruffelder C, Isidoga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinmaier RM. Dendritic cells require a systemic type I interferon response to mature and induce CD4 T helper 1 immunity with poly IC as adjuvant. J Exp Med. 2009;206(7):1589–602.
14. Bauer DL, Kurtz JR, Grant SB, Immethun VE, McLachlan JB. Adjuvant combinations activate dendritic cells and contribute to antigen-specific CD4 T cell expansion. J Immunol 2020, 204(1 Supplement):166:115–116.15. Suspi T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N, Kobayashi Y, Mi Limani M, Yokota S. A Cpg-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphertheria–tetaanus–pertussis vaccine. Vaccine. 2005;23(46):5450–6.
16. Stils HF Jr. Adjuvants and antibody production: dispelling the myths associated with friends’ complete and other adjuvants. ILAR J. 2005;46(3):280–93.
17. Comberato A, Palaoja K, Basting MM. Nucleic acids presenting polymer nanomaterials as vaccine adjuvants. J Mater Chem B. 2019;7(41):6321–46.
18. Hogenesch J. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2013;3:406–406.
19. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 2011;239(1):178–96.
20. Diebold SS, Kaisto T, Hemmi H, Akira S. Toll-like receptor 7 activation Enhances CD8 T Cell Effector Functions by Promoting Cellular Glycolysis. Front Immunol. 2018;9:2874.
21. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 Nature. 2001;413(6857):732–8.
22. Martins KA, Baviari S, Salazar AM. Vaccine adjuvant uses of polyc-Ic and derivatives. Expert Rev Vaccines. 2015;14(3):447–59.
23. Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Trumpfheller C, Trumpfheller, Salazar AM. Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vaccines. 2015;14(3):447–59.
24. Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Trumpfheller C, Trumpfheller, Salazar AM. Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vaccines. 2015;14(3):447–59.
25. Komal A, Noreen M, El-Kott AF. TLR3 agonists: RGC100, ARNAX, and poly-IC: A New RNA-based adjuvant enhances Th1 immunity: update on Toll-like receptor 3. Front Immunol. 2018;9:2874.
26. Li Q, Yan Y, Liu J, Huang X, Zhang X, Kirschning C, Xu HC, Lang PA, Dittmer U, Zhang E, et al. Toll-Like Receptor 7 Activation Enhances CD8+ T Cell Effector Functions by Promoting Cellular Glycolysis. Front Immunol. 2019;10:2191–2191.
27. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2001;2(15):373–8.
28. Li Q, Yan Y, Liu J, Huang X, Zhang X, Kirschning C, Xu HC, Lang PA, Dittmer U, Zhang E, et al. Toll-Like Receptor 7 Activation Enhances CD8+ T Cell Effector Functions by Promoting Cellular Glycolysis. Front Immunol. 2019;10:2191–2191.
29. Komal A, Noreen M, El-Kott AF. TLR3 agonists: RGC100, ARNAX, and poly-Ic: A comparative review. Immunol Res. 2021;69(4):312–22.
30. Oh JZ, Kuchte BS, Buchill MA, Kedl RM. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood. 2011;118(11):3028–38.
31. Ziegler A, Solder C, Lienkenlau S, Spanier J, Trittlet S, Riese P, Kramps T, Weiss S, Heidenreich R, Jasny E, et al. A New RNA-based adjuvant enhances virus-specific vaccine responses by locally Triggering TLR- and IL12-Dependent Effects. J Immunol. 2017;198(4):1595–605.
32. Negishi H, Yonai H, Nakajama A, Koshiba H, Arai T, Kobayashi K, Matsuda A, Matsuki K, Miki S, Doi T, Aderem A et al. Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat Immunol 2012, 13(7):659–666.

Kwangmyong, Republic of Korea. 4 Department of Microbiology, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.

Gwangmyeong, Republic of Korea. 4 Department of Microbiology, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.
31. Hoehnkeier K, Klein M, Gottschalk C, Hoss F, Scheu S, Coch C, Hartmann G, Kurs C. Cutting Edge: The RIG-I Ligand 3′ΔR Potently Improves CTL Cross-Priming and Facilitates Antiviral Vaccination. J Immunol. 2016;196(8):2439–43.
32. Bourquin C, Schmidt L, Lanz AL, Storch B, Wurzenberger C, Anz D, Sandholzer N, Mocikat R, Berger M, Poecck H, et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J Immunol. 2009;183(10):6078–86.
33. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen XJ, et al. Ascophyllan purified from Ascophyllum nodosum induces Th1 and Tc1 immune responses to CD103+ dendritic cells. J Immunol. 2015;194(3):1294–304.
34. Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheu S, Coch C, Hartmann G, et al. Cricket paralysis virus internal ribosome entry site (IRES)-derived 5′UTR, Kim H-J, et al. Cricket paralysis virus internal ribosome entry site (IRES)-derived 5′UTR.
35. Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheu S, Coch C, Hartmann G, et al. Cricket paralysis virus internal ribosome entry site (IRES)-derived 5′UTR.
36. Zhang W, Du J-Y, Jiang Z, Okimura T, Oda T, Yu Q, Jin J-O. Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant. J Exp Med. 1996;183(3):751–7.